Compare IKT & PLBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IKT | PLBY |
|---|---|---|
| Founded | 2008 | 1953 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Recreational Games/Products/Toys |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.5M | 204.4M |
| IPO Year | 2020 | 2020 |
| Metric | IKT | PLBY |
|---|---|---|
| Price | $2.04 | $1.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $5.00 | $3.00 |
| AVG Volume (30 Days) | 887.2K | ★ 1.0M |
| Earning Date | 03-26-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 57.76 | ★ 87.50 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $120,928,000.00 |
| Revenue This Year | N/A | $9.17 |
| Revenue Next Year | N/A | $7.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 4.13 |
| 52 Week Low | $1.33 | $1.12 |
| 52 Week High | $2.26 | $2.75 |
| Indicator | IKT | PLBY |
|---|---|---|
| Relative Strength Index (RSI) | 66.00 | 35.57 |
| Support Level | $1.59 | N/A |
| Resistance Level | $2.13 | $1.94 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 73.53 | 11.34 |
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.